Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Advertisements

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.

From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.

Date of download: 11/13/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Reality of Heart Failure in Latin America J.

Figure 1 Initial management of a patient with acute heart failure

Supplementary Figure 4. Kaplan-Meier curves of 12-month readmission free survival rates according to renal dysfunction with subclassification in all (A),

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Representative longitudinal strain analysis in an apical two-chamber view. The view is presented in the left panel and the longitudinal strain.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Prevalence of functional mitral regurgitation according to NYHA functional class (A; P

Nat. Rev. Cardiol. doi: /nrcardio

Reproduced with permission from Yancy, C. W. et al. 2017

Figure 5 BMI and cardiorespiratory fitness levels

Figure 8 Implanted devices for the management of heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Energy supply–demand matching in health and heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Three-year survival rates on the basis of body composition

Figure 7 European Society of Cardiology 2016

Figure 2 Physical activity and obesity levels by WHO-designated region and sex Figure 2 | Physical activity and obesity levels by WHO-designated region.

Figure 3 Traditional geometry and spatial fractals

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Prevalence of HFpEF and HFrEF by age

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Figure 1 Decision tree integrating the assessment,

Figure 2 Global cost of HF per capita in 2012

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Wayne L. Miller et al. JCHF 2013;1:

Figure 9 Management of atrial fibrillation

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Cumulative survival without events during 1 year in patients with preserved systolic function (left ventricular ejection fraction (LVEF) >40%) and with.

Associations between presence of tachycardia at time of admission (heart rate ≥120/min) and the primary composite outcome of death or cardiovascular rehospitalisation,

Supplementary Figure 4. Kaplan-Meier curves of 12-month readmission free survival rates according to renal dysfunction with subclassification in all (A),

Figure 3. Survival rates according to renal dysfunction

Ejection fraction preoperatively and at follow-up in conventional (C) and no-touch (NT) groups. Ejection fraction preoperatively and at follow-up in conventional.

Connie W. Tsao et al. JCHF 2016;4:

Multivariate Cox survival analysis with predictors of mortality after adjusting for comorbidities and DBT. COPD, chronic obstructive pulmonary disease;

EFFECTS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS ON MORTALITY, CARDIOVASCULAR HOSPITALIZATION AND FUNCTIONAL CAPACITY IN PATIENTS WITH HEART.

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Average left ventricular ejection fraction (LVEF) values during the 1 year of observation in patients with preserved systolic function (LVEF >40%) and.

Lifetime heart failure risk*

Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular.

Orly Vardeny et al. JCHF 2016;4:

Time to first event analysis revealed a significant difference in estimated event-free (death or hospitalisation) survival between patients with left ventricular.

Adjusted cumulative incidence of stroke, by sex and heart failure status. Adjusted cumulative incidence of stroke, by sex and heart failure status. The.

Relationship between 6-month all-cause mortality and the three types of heart failure adjusted for age ≥75 years, peripheral edema at admission, systolic.

Adjusted cumulative disability incidence by sex and heart failure status. Adjusted cumulative disability incidence by sex and heart failure status. The.

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.65 Figure 9 Comparative mortality in HFpEF and HFrEF from the MAGGIC study Figure 9 | Comparative mortality in HFpEF and HFrEF from the MAGGIC study51. a | Age-adjusted and comorbidity-adjusted all-cause mortality in heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) are shown. b | Adjusted hazard ratios for mortality in HFpEF versus HFrEF according to types of studies (randomized clinical trials [RCT] or observational studies [OBS]) are shown along with the adjusted annualized mortality. c | Effect of lower ejection fraction (EF; relative to an EF ≥60%) on adjusted risk of all-cause (left) and cardiovascular (right) death. Panels a and c modified from Meta-analysis Global Group in Chronic Heart Failure. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur. Heart J. 33 (14), 1750–1757 (2012), with permission from Oxford University Press and the European Society of Cardiology. Panels a and c modified from Meta-analysis Global Group in Chronic Heart Failure. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur. Heart J. 33 (14), 1750–1757 (2012), with permission from Oxford University Press and the European Society of Cardiology Dunlay, S. M. et al. (2017) Epidemiology of heart failure with preserved ejection fraction Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.65